In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
|Articles|January 23, 2016
Prescription Drug Trends, Diabetes Risk in Cancer Survivors Highlight Week in Health Care News
Author(s)Davy James, Managing Editor
Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.
Advertisement
[<a href="//storify.com/pharmacytimes/prescription-drug-trends" target="_blank">View the story "Prescription Drug Trends, Diabetes Risk in Cancer Survivors Highlight Week in Health Care News" on Storify</a>]
Advertisement
Related to this article
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Two recent graduates share strategies for standing out in the competitive fellowship application process.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5